The sevoflurane source market size is estimated to reach US$250 million by 2027 after growing at a CAGR of around 1.7% from 2022 to 2027. The sevoflurane is general anesthesia that reduces the activity of central nervous system in the body. It is an ether compound that has fluoromethyl and 1, 1, 1, 3, 3, 3-hexafluroisopropyl as alkyl groups.